Growth hormone-releasing peptides as negative modulators of atherosclerosis and hypercholesterolemia
CA 2399548 A1 · Owner: Ong, Huy · Inventors: Ong, Huy; Marleau, Sylvie; Tremblay, Andre
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Growth hormone releasing peptides (GHRPs) a family of synthetic analogs, modelled from Met-enkephalin have been found to bind a novel class of specific GHRP, receptors in the mammalian heart that are distinct from the pituitary GHRP receptors, involved in GH secretion. CD36 a multifunctional B-type scavenger receptor has been, identified as the unique GHRP binding site in the heart. CD36 mediates the uptake of, lipoproteins into a number of cell types and was recognized to play a crucial role in, scavenging oxidized low density lipoproteins in monocyte/ macrophages leading to foam, cell formation, a key step in fatty streaks formation. The hexapeptide GHRP prototypes hexarelin (His - …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 23, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.